M&A Deal Summary

Vertex Pharmaceuticals Acquires Alpine Immune Sciences

On April 10, 2024, Vertex Pharmaceuticals acquired life science company Alpine Immune Sciences for 4.9B USD

Acquisition Highlights
  • This is Vertex Pharmaceuticals’ 8th transaction in the Life Science sector.
  • This is Vertex Pharmaceuticals’ largest (disclosed) transaction.
  • This is Vertex Pharmaceuticals’ 7th transaction in the United States.
  • This is Vertex Pharmaceuticals’ 1st transaction in Washington.

M&A Deal Summary
Date 2024-04-10
Target Alpine Immune Sciences
Sector Life Science
Buyer(s) Vertex Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 4.9B USD
Advisor(s) Centerview Partners (Financial)
Fenwick & West (Legal)

Target

Alpine Immune Sciences

Seattle, Washington, United States
Alpine Immune Sciences is focused on developing novel protein-based immunotherapies using its proprietary variant immunoglobulin domain (vIgD™) platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a unique process known as directed evolution, which can produce proteins capable of either enhancing or diminishing an immune response and thereby may apply therapeutically to both oncology and inflammatory diseases. Alpine Immune Sciences was founded in 2007 and is based in Seattle, Washington.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Vertex Pharmaceuticals

Boston, Massachusetts, United States
Category Company
Founded 1989
Sector Life Science
Employees5,400
Revenue 9.9B USD (2023)
DESCRIPTION

Vertex Pharmaceuticals is a biotechnology company that aims to discover, develop, and commercialize innovative new medicines so people with serious diseases can lead better lives. Vertex Pharmaceuticals was founded in 1989 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 8 of 8
Sector (Life Science) 8 of 8
Type (Add-on Acquisition) 6 of 6
State (Washington) 1 of 1
Country (United States) 7 of 7
Year (2024) 1 of 1
Size (of disclosed) 1 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-11 ViaCyte

San Diego, California, United States

ViaCyte is a private cellular therapy company with a clinical-stage stem cell platform that delivers therapeutic proteins to restore health in people. The company has significant clinical experience in patients with T1D; this includes a first-in-class gene-edited, immune-evasive investigational islet cell replacement therapy for diabetes that could potentially eliminate the need for exogenous insulin without requiring immunosuppression. It has received support for its research from JDRF and the California Institute of Regenerative Medicine and has established collaborative partnerships with leading companies, including CRISPR Therapeutics, to advance its therapies for T1D. ViaCyte is based in San Diego, California.

Buy -
Mergr

Product

Company

Legal